Mohsen Hejrati is co-founder and CEO at Clusterone. Prior to founding Clusterone, he was a research engineer at Waymo and senior researcher at Vicarious. At Clusterone, he is focused on large scale machine learning platforms for applications in life sciences and the autonomous vehicles industry. His research interests span computer vision and machine learning. Mohsen has published in IEEE Conference of Computer Vision and Pattern Recognition (CVPR), European Conference on Computer Vision (ECCV) and Neural Information Processing Systems (NIPS) among others. Read his full bio.

Interview with Mohsen Hejrati from Clusterone

Q: What need is Clusterone addressing?

A: AI and machine learning are becoming cornerstone technologies for scientists and engineers, but access to these technologies is still cumbersome. Machine learning – and deep learning in particular – requires lots of computing power, which is challenging to set up and manage. In addition, not all companies have the necessary expertise to apply machine learning and AI. Clusterone helps them solve those complex engineering tasks and takes care of setup, maintenance, and orchestration of the infrastructure behind AI. We enable scientists and engineers to run experiments – even distributed deep learning code – with the click of a button.

A few decades ago, using a computer to do work was really hard, today this has become the easiest thing in the world. We want AI to be the same way. No fiddling around, no complex setup, it should be a tool to get work done, not a time sink.

Q: What are the products and/or services Clusterone offers/develops to address this need? What makes Clusterone unique?

A: We offer the Clusterone deep learning platform – think of it as an operating system for AI – as well as professional engineering and research services through our Applied AI team. Our platform removes the need for infrastructure setup and orchestration. It also allows teams to collaborate on deep learning experiments and easily reproduce previous experiments. Clusterone is an enterprise-grade platform and we work closely with our customers to make sure they get the most out of their AI investments.

The platform is infrastructure-agnostic, meaning it can run on any on-premises cluster or public cloud, as well as integrate into existing workflows. We help teams to use their hardware more efficiently by optimizing cluster utilization and thus saving our customers time and money.

Q: What is your role at Clusterone and what excites you about your work?

A: I am the CEO and co-founder of Clusterone. The AI industry is incredibly fast-moving, and I believe we’re at a crucial turning point where AI moves from labs into mainstream engineering. Being part of this development is very exciting. AI has huge potential for many industries, but precision medicine and biotech stand out in particular. We want to be part of the cure for cancer, aging, and many other pressing problems that we face today. I think that is very exciting.

Q: When thinking about Clusterone and the domain Clusterone is working in, what are some of the recent breakthroughs that are propelling the field forward and how will they impact healthcare?

A: On the hardware side, the biggest breakthrough has been how capable and affordable GPUs and computing power in general has become. Cloud providers make it very simple to access this computing power today, which is a very important step.
When it comes to software, I believe the development of free and open-source resources has been very important. Public datasets and libraries such as TensorFlow and PyTorch make it very easy to get started with AI today.

These developments will have great impact on healthcare through innovative new diagnostic and analysis technologies (e.g. automated cancer cell detection using computer vision). For doctors and hospitals, it is becoming much easier to gain insights from medical imaging and other data they collect. That way, they’re able to help patients more directly and more individually.

Q: What are the short-term challenges that Clusterone and its peers are facing?

A: The market for AI is still young, knowledge about AI, machine learning, and even data science is still not widely available. There’s also a severe talent shortage for AI and machine learning experts. We have to work to educate people about AI and train new talent.

Also, Hardware and Software solutions are evolving at a rapid pace which makes adopting and maintaining any solution especially challenging. At Clusterone, we’re working hard to stay ahead of these developments and to simplify this complexity for our customers by providing a concise user experience across all types of infrastructure.

Q: Is there anything else you would like to share with the PMWC audience?

A: We are excited to see a growing community of life science practitioners focusing on adopting machine learning for the right problems. We see ourselves serving them to build the next breakthroughs in cancer research and personalized medicine.

Interview with Ralph Snyderman from Duke University

Q: What research are you or your lab focusing on and why, and what problem(s) are you trying to solve?

A: My work involves designing, implementing and studying innovations in medical education that allow our medical schools to fulfill our social contract to improve the health of our communities and reduce the suffering of our patients.

Read More

Interview with Catherine Reinis Lucey from UCSF

Q: What research are you or your lab focusing on and why, and what problem(s) are you trying to solve?

A: My work involves designing, implementing and studying innovations in medical education that allow our medical schools to fulfill our social contract to improve the health of our communities and reduce the suffering of our patients.

Read More

Interview with Gunnar Carlsson from Ayasdi

Q: What need is Ayasdi addressing?

A: Ayasdi is pioneering the application of artificial intelligence to value-based care by targeting two of the most complex problems in healthcare: population risk stratification and clinical variation management.

Read More

Interview with Nikole Kimes from Siolta Therapeutics

Q: What need is Siolta Therapeutics addressing?

A: Chronic diseases, including inflammatory diseases such as asthma, now represent the leading cause of mortality and morbidity worldwide.

Read More

Note from Dr. Patrick Conway, President & CEO, Blue Cross and Blue Shield NC to PMWC

VC activity is booming in healthcare, with second quarter drawing in $5.1 billion in capital. That is 22% of the total $23 billion raised by all VC-based companies in the U.S., according to latest Pricewaterhouse Coopers quarterly report.

Read More

Interview with Atul Sharan, Co-founder and CEO, CellMax Life

Q: CellMax has developed non-invasive blood tests based on Circulating tumor cells CTC. How do you see these tests being adopted clinically?

A: Survival rates are greater than 90% for cancers that are detected at an early stage.

Read More

Interview with Wendell Jones from Q² Solutions | EA Genomics

Q: What need is Q² Solutions | EA Genomics addressing?

A: As a leading provider of genomic services in clinical trials and discovery, Q² Solutions | EA Genomics advances science by harnessing technological expertise to drive understanding of the human genome and disease biology to detect the effects of therapies.

Read More

Interview with Ben Solomon from GeneDx

Q: What need is GeneDx addressing?

A: GeneDx was started in 2000 by two NIH scientists with the mission of making genetic testing accessible for patients with rare diseases.

Read More

Interview with Ty Ridenour from RTI International

Q: What need is RTI International addressing?

A: As an independent research institute, RTI is dedicated to improving the human condition. We answer questions that demand an objective and multidisciplinary approach—one that integrates expertise across the social and laboratory sciences, engineering, and international development.

Read More

Interview with Madhuri Hegde, Vice President and Chief Science Officer of PerkinElmer’s Global Laboratory Services

Q: What need is Global Laboratory Services addressing?

A: PerkinElmer Genomics is global (genomics) laboratory service with laboratories in US, India and China, addressing genetic/genomic testing across the globe.

Read More

Interview with Rita R. Colwell from University of Maryland College Park and John Hopkins School of Public Health

Q: What research are you or your lab focusing on and why, and what problem(s) are you trying to solve?

A: The research that I am focusing on is understanding the microbiome of the human system and the environment, which means understanding the gut flora and its relationship to health and disease.

Read More

Interview with Dr. Nicholas Dracopoli from Personal Genome Diagnostics

Q: What need is Personal Genome Diagnostics (PGDx) addressing?

A: PGDx is developing standardized, clinical Next Generation Sequencing (NGS) kits to help enable effective treatment decisions for cancer patients.

Read More

Interview with Mohsen Hejrati from Clusterone

Q: What need is Clusterone addressing?

A: AI and machine learning are becoming cornerstone technologies for scientists and engineers, but access to these technologies is still cumbersome.

Read More

VC Investment in Precision Medicine Boomed in Q2 Mega-deals Hitting Record Levels

VC activity is booming in healthcare, with second quarter drawing in $5.1 billion in capital. That is 22% of the total $23 billion raised by all VC-based companies in the U.S., according to latest Pricewaterhouse Coopers quarterly report.

Read More

Interview with Patrick Conway from Blue Cross and Blue Shield of North Carolina

Q: In the past, you served as director of the Center for Medicare and Medicaid Innovation. What are you most proud of accomplishing at CMMI?

A: During my tenure at the Centers for Medicare and Medicaid Services, one of my many roles included serving as the Director of the Center for Medicare and Medicaid Innovation.

Read More
University of Michigan

The Precision Medicine World Conference (PMWC), held annually in Silicon Valley, is coming back to North Carolina for its 2nd Conference back at Duke University on September 24-25, 2018.

PMWC 2018 Duke, the 15th installment of the conference, will spotlight the explosion of biomedical technologies, driving initiatives that enable the translation of precision medicine into direct improvements in health care.

 

  • Track 1 will showcase sessions on the latest advancements in precision medicine which include, but are not limited to:
    • Digital Phenotyping
    • Precision Public Health
    • Pharmacogenomics
    • The Microbiome
    • Rare Disease Diagnosis
    • Digital Health/Health and Wellness
    • Early Days of Life Sequencing
    • Diversity in Precision Medicine
    • Resilience
    • AI and Machine Learning
    • Gene Editing
    • Large Scale Bio-data Resources to Support Drug Development (PPPs)
    • Point-of Care Dx Platform
    • FDA Efforts to Accelerate PM
    • Implementation into Health Care Delivery
    • Next Gen. Workforce of PM
    • Immunotherapy
    • Robust Clinical Decision Support Tools
    • Creating Clinical Value with Liquid Biopsy ctDNA, etc.
    • Neoantigens
    • Emerging Technologies In PM

The Precision Medicine World Conference (PMWC), held annually in Silicon Valley, is coming back to North Carolina for its 2nd Conference back at Duke University on September 24-25, 2018.

PMWC 2018 Duke, the 15th installment of the conference, will spotlight the explosion of biomedical technologies, driving initiatives that enable the translation of precision medicine into direct improvements in health care.

 

    • Track 1 will showcase sessions on the latest advancements in precision medicine which include, but are not limited to:
      • Digital Phenotyping
      • Precision Public Health
      • Pharmacogenomics
      • The Microbiome
      • Rare Disease Diagnosis
      • Digital Health/Health and Wellness
      • Early Days of Life Sequencing
      • Diversity in Precision Medicine
      • Resilience
      • AI and Machine Learning
      • Gene Editing
      • Large Scale Bio-data Resources
        to Support Drug Development (PPPs)
      • Point-of Care Dx Platform
      • FDA Efforts to Accelerate PM
      • Implementation into Health Care Delivery
      • Next Gen. Workforce of PM
      • Immunotherapy
      • Robust Clinical Decision Support Tools
      • Creating Clinical Value with Liquid Biopsy
        ctDNA, etc.
      • Neoantigens
      • Emerging Technologies In PM
  • Track 2- PMWC 2018 Duke Showcase, will enable 15-minute company presentations on latest novel technologies. Apply to present here.
big data diagnostics session

Clinical Dx Showcase

crispr showcase

Emerging Therapeutics Showcase

NGS Showcase

Genomic Profiling Showcase

AI Showcase Session Image

AI and Data Sciences Showcase

  • Luminary and Pioneer Awards, honoring individuals who contributed, and continue to contribute, to the field of Precision Medicine
  • 500+ multidisciplinary attendees, from across the entire spectrum of healthcare, representing different types of companies, technologies, and medical centers with leadership roles in precision medicine

[chimpy_lite_form]

pmwc-newsletter-img

Don't Miss Important Precision Medicine Updates

PMWC is the most comprehensive precision medicine conference. To recieve the lastest news and updates from the field, subscribe to the newsletter here.

You have Successfully Subscribed!